ArticleJournal of Korean medical science2009

Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy.

Hye-Suk Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.